Inotuzumab Ozogamicin Approved in the US for Adult Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Today the US Food and Drug Administration approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Listen to Dr Elias Jabbour of the MD Anderson Cancer Center provide expert commentary and insights on the clinical trial data leading to the US approval of inotuzumab ozogamicin.

primelines-approved

Clinical Opinion Poll

What best describes your treatment approach to 54 y/o patient with FIGO IIIB serous ovarian cancer who underwent debulking surgery?